Activin receptor signaling regulates prostatic epithelial cell adhesion and viability1 www.neoplasia.com

Neoplasia

Volumn 11, Issue 4, 2009, Pages 365-376

  Simon, Derek P ^a   Meethal, Sivzin Vadakkadath ^a   Wilson, Andrea C ^a   Gallego, Miguel J ^a   Weinecke, Stephanie L ^a   Bruce, Erin ^a   Lyons, Patrick F ^b   Haasl, Ryan J ^a   Bowen, Richard L ^c   Atwood, Craig S ^a,d,e  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c OTB Research   (United States)

^d EDITH COWAN UNIVERSITY   (Australia)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ACTIVIN RECEPTOR 2; ADAM 15 PROTEIN; ADAM PROTEIN; CASPASE 3; FIBROBLAST GROWTH FACTOR; INHIBIN A; SMAD2 PROTEIN; UNCLASSIFIED DRUG; ACTIVIN; ACTIVIN RECEPTOR TYPE II A; ACTIVIN RECEPTOR TYPE II-A; ADAM15 PROTEIN, HUMAN; MEMBRANE PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ADHESION; CELL FATE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; FETAL CALF SERUM; HUMAN; HUMAN CELL; MALE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL SURVIVAL; CYTOLOGY; EPITHELIUM CELL; IMMUNOBLOTTING; METABOLISM; NEUROBLASTOMA; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ADAM PROTEINS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; EPITHELIAL CELLS; HUMANS; IMMUNOBLOTTING; MALE; MEMBRANE PROTEINS; NEUROBLASTOMA; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 65549152288     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.8044     Document Type: Article

References (100)

1. McCullough KD, Coleman WB, Smith GJ, and Grisham JW (1997). Age- dependent induction of hepatic tumor regression by the tissue microenvironment after transplantation of neoplastically transformed rat liver epithelial cells into the liver. Cancer Res 57, 1807-1813.
2. McCullough KD, Coleman WB, Ricketts SL, Wilson JW, Smith GJ, and Grisham JW (1998). Plasticity of the neoplastic phenotype in vivo is regulated by epigenetic factors. Proc Natl Acad Sei USA 95, 15333-15338. (Pubitemid 29018699)
3. Coleman WB, McCullough KD, Esch GL, Paris RA, Hixson DC, Smith GJ, and Grisham JW (1997). Evaluation of the differentiation potential of WB-F344 rat liver epithelial stem-like cells in vivo. Differentiation to hepatocytes after transplan- tation into dipeptidylpeptidase-IV-deficient rat liver. AmJPaéol 151, 353-359. (Pubitemid 27330056)
4. Lee LM, Seftor EA, Bonde G, Cornell RA, and Hendrix MJ (2005). The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dyn 233, 1560-1570. (Pubitemid 40995154)
5. Topczewska JM, Postov. it LM, Margaryan NV, Sam A, Hess AR, Wheaton WW, Nickoloff BJ, Topczewski J, and Hendrix MJ (2006). Embryonic and tumori- genic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 12, 925-932.
6. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, and Postovit LM (2007). Reprogramming metastatic tumour cells with embryonic micro- environments. Nat Rev Cancer 7, 246-255. (Pubitemid 46480969)
7. Maffini MV, Calabro JM, Soto AM, and Sonnenschein C (2005). Stromal regu- lation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma. Am J Pathol 167, 1405-1410. (Pubitemid 41541426)
8. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, and Rekasi Z (2000). Peptide analogs in the therapy of prostate cancer. Prostate 45, 158-1.66.
9. Miyamoto H, Messing EM, and Chang C (2004). Androgen deprivation therapy for prostate cancer: current status and. future prospects. Prostate 61, 332-353. (Pubitemid 39571710)
10. Sharifi N, GulleyJL, and Dahut WL (2005). Androgen deprivation therapy for prostate cancer. JAMA 294, 238-244. (Pubitemid 41043794)
11. Navarro D, Luzardo OP Fernandez L, Chesa N, and. Diaz-Chico BN (2002). Transition to androgen-independence in prostate cancer. J. Steroid Biochem MoI Biol 81, 191-201.
12. Lee EC and Tenniswood MP (2004). Emergence of metastatic hormone- refractory disease in prostate cancer after anti-androgen therapy. J. Cell Biochem 91, 662-670.
13. Barki-Harrington L and Daaka Y (2001). Bradykinin induced mitogenesis of androgen independent prostate cancer cells. /Urol 165, 2121-2125. (Pubitemid 32453565)
14. Berteaux N, Lottin S, Adriaenssens E, Van Coppenolle F, Leroy X, Coll J, Dugimont T, and Curgy JJ (2004). Hormonal regulation of H19 gene expres- sion in prostate epithelial cells. J. Endocrinol 183, 69-78. (Pubitemid 40124644)
15. Miyazaki H, Watabe T, Kitamura T, and Miyazono K (2004). BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23, 9326-9335. (Pubitemid 40069665)
16. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, and Sawyers CL (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10, 33-39. [1.7] Suzuki H, Ueda T, Ichikawa T, and Ito H (2003). Androgen receptor involve- ment in the progression of prostate cancer. Endocr ReUt Cancer 10, 209-216. (Pubitemid 38524696)
17. Bahk JY, Hyun JS, Lee H, Kim MO, Cho GJ, Lee BH, and Choi WS (1998). Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in. prostate cancer cells and. effect of GnRH on the proliferation of prostate cancer cells. Urol Res 26, 259-264. (Pubitemid 28416998)
18. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH.) and LHRH. receptor gene expression in human prostate cancers. /Urol 163, 623-629. (Pubitemid 30060537)
19. Gnanapragasam VJ, Darby s, Khan MM, lock WG, Robson CN, and Leung HY (2005). Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refrac- tory prostate cancer
20. Halmos G, Arencibia JM, Schally AV, Davis R, and Bostwick DG (2000). High incidence of receptors for luteinizing hormone-releasing hormone (LHRH.) and LHRH. receptor gene expression in human prostate cancers. J. Urol 163, 623-629. (Pubitemid 30060537)
21. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, and Leung HY (2005). Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refrac- tory prostate cancer. J. Pathol 206, 205-213. (Pubitemid 40754024)
22. Ben-Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, Porter AT, and Tang DG (1999). Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J. Urol 161, 970-976. (Pubitemid 29422418)
23. Wang QF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley WF Jr, and Sluss PM (1996). Activin inhibits basal, and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology 137, 5476-5483. (Pubitemid 26423113)
24. Dalkin AC, Gilrain JT, Bradshaw D, and Myers CE (1996). Activin inhibition of prostate cancer cell growth: selective actions on. androgen-responsive LNCaP cells. Endocrinology 137, 5230-5235. (Pubitemid 26423078)
25. van Schaik RH, Wierikx CD, Timmerman MA, Oomen MH, van Weerden WM, van der Kwast TH, van Steenbrugge GJ, and de Jong FH (2000). Varia- tions in activin receptor, inhibin/activin subunit and follistatin mRNAs in hu- man prostate tumour tissues. Br J Cancer 82, 1.12-11.7. (Pubitemid 30008968)
26. Thomas TZ, Chapman SM, Hong W, Gurusingfhe C, Mellor SL, Fletcher R, Pedersen J, and Risbridger GP (1998). Inhibins, activins, and follistatins: expres- sion, of mRNAs and cellular localization in tissues from, men with, benign pros- tatic hyperplasia. Prostate 34, 34-43. (Pubitemid 28023824)
27. Dimhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, and Berger P (1998). Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 35, 212-220. (Pubitemid 28211295)
28. McPherson SJ, Mellor SL, Wang H, Evans LW, Groóme NP, and Risbridger GP (1999). Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 140, 5303-5309. (Pubitemid 30660240)
29. Thomas TZ, Wang H, Nielasen P, O'Bryan MK, Evans LW, Groóme NP, Pedersen J, and Risbridger GP (1997). Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J. Clin Endocrinol Metab 82, 3851-3858. (Pubitemid 27509382)
30. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, and Rini G (2006). Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 23, 117-1.22. (Pubitemid 44440171)
31. Kaighn ME, Lechner JF, Narayan KS, and Jones LW (1978). Prostate carci- noma: tissue culture cell lines. Natl Cancer Inst Monogr 49, 17-21. (Pubitemid 9152618)
32. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, and Jones LW (1979). Estab- lishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17, 1.6-23. (Pubitemid 9239413)
33. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, et al. (1980). The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37, 115-132.
34. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, and Murphy GP (1983). LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-1818.
35. Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, and Atwood CS (2004). Luteinizing hormone, a reproductive regulator that modu- lates the processing of amyloid-beta precursor protein and amyloid-beta depo- sition. J. Biol Chem 279, 20539-20545. (Pubitemid 38623501)
36. Chahal HS and Drake WM (2007). The endocrine system and ageing. J. Pathol 211, 173-180. (Pubitemid 46195515)
37. Bowen RL and. Atwood CS (2004). Living and dying for sex. A theory of aging based on the modulation of cell cycle signaling by reproductive hormones. Gerontology 50, 265-290.
38. Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, and Saito S (1996). Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin Endocrinol Metab 81, 21.25-2130. (Pubitemid 26176707)
39. Welt C, Sidis Y, Keutmann H, and Schneyer A (2002). Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med 227, 724-752.
40. Pangas SA and Woodruff TK (2000). Activin. signal transduction pathways. Třené Endocrinol Metab 11, 309-314.
41. Abe Y, Minegishi T, and Leung PC (2004). Activin receptor signaling. Growth Factors 22, 105-110. (Pubitemid 38923314)
42. Xu G, Zhou H, Wang Q, Auersperg N, and. Peng C (2006). Activin. receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell Unes. Mol Cancer Res 4, 235-246.
43. Lebrun JJ, Takabe K, Chen Y, and. Vale W. (1999). Roles of pathway-spedfic and inhibitory Smads in activin receptor signaling. MoI Endocrinol 13, 15-23. (Pubitemid 29149247)
44. Wu JW, Hu M, Chai J, Seoane J, Huse M, Li C, Rigotti DJ, Kyin S, Muir TW, Fairman R, et al. (2001). Crystal structure of a phosphorylated Smad2. Recog- nition of phosphoserine by the MH2 domain and insights on Smad function, in TGF-beta signaling. MoI Cell 6, 1277-1289. (Pubitemid 34084999)
45. Wu JW, Fairman R, Penry J, and Shi Y (2001). Formation of a stable hetero- dimer between Smad2 and Smad4. J. Biol Chem 276, 20688-20694. (Pubitemid 37411157)
46. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, and Cataldo D (2008). Emerging roles of ADAM and ADAMTS met al.loproteinases in cancer. Biochimie 90, 367-379.
47. Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, and Day ML (2006). ADAMl 5 disintegrin is as- sociated with aggressive prostate and breast cancer disease. Neoplasia 6, 31.9-329.
48. Yamada D, Ohuchida K, Mizumoto K, Ohhashi S, Yu J, Egami T, Fujita H, Nagai E, and Tanaka M (2007). Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res 27, 793-799. (Pubitemid 46586983)
49. Martin J, Eynstone LV Davies M, Williams JD, and Steadman R (2002). The role of ADAM 15 in glomerular mesangial cell migration. /Biol Chem 277, 33683-33689.
50. Charrier-Hisamuddin L, Laboisse CL, and Merlin D (2008). ADAM-15: a met al.lo- protease that mediates inflammation. FASEB J 22, 641-653.
51. Nakamoto T, Chang CS, Li AK, and Chodák GW (1992). Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 52, 571-577.
52. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, et al. (1997). Basic fibroblast growth, factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31, 223-233. (Pubitemid 27247313)
53. Dorkin TJ, Robinson MC, Marsh. C, Neal DE, and Leung HY (1999). aFGF immunoreactivity in. prostate cancer and its co-localization with bFGF and FGF8. J Pathol 189, 564-569.
54. Ludwig TE, Bergendahl V, Levenstein ME, Yu J, Probasco MD, and Thomson JA (2006). Feeder-independent culture of human embryonic stem cells. Nat Methods 3, 637-646. (Pubitemid 44123431)
55. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, and Pollak M (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566. (Pubitemid 28067285)
56. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, and Adami HO (1997). Insulin-like growth, factor 1 in relation, to prostate cancer and benign prostatic hyperplasia. Br J' Cancer 76, 1115-1118.
57. WoIk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P Adami HO, and Trichopoulos D (1998). Insulin-like growth, factor 1 and pros- tate cancer risk: a population-based, case-control study. J. Natl Cancer Inst 90, 911-915. (Pubitemid 28304159)
58. Connolly JM and Rose DP (1990). Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 16, 209-218. (Pubitemid 20231868)
59. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, and Kozlowski JM (1991). Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51, 2780-2785.
60. Carruba G, Leake RE, Rinaldi F, Chalmers D, Comito L, Sorci C, Pavone- Macaluso M, and Castagnetta LA (1994). Steroid-growth factor interaction in human prostate cancer. 1: Short-term effects of transforming growth factors on growth of human prostate cancer cells. Steroids 59, 412-420. (Pubitemid 24226900)
61. McEleny KR, Watson RW, Coffey RN, O'Neill AJ, and Fitzpatrick JM (2002). Inhibitors of apoptosis proteins in prostate cancer cdl lines. Prostate 51, 133-140.
62. Risbridger GP, Schmitt JF, and Robertson DM (2001). Activins and inhibins in endocrine and. other tumors. Endocr Rev 22, 836-858. (Pubitemid 34214298)
63. Chen YG, Lui HM, Lin SL, Lee JM, and Ying SY (2002). Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood) 227, 75-87.
64. Risbridger GP, Thomas T, Gurusinghe CJ, and McFarlane JR (1996). Inhibin- related proteins in rat prostate. J. Endocrinol 149, 93-99. (Pubitemid 26135221)
65. Al-Omari R, Shidaifat F, and Dardaka M (2005). Castration induced changes in dog prostate gland associated with diminished activin and activin receptor expression. Life Sei 77, 2752-2759.
66. Cancilla B, Jarred RA, Wang H, Mellor SL, Cunha GR, and Risbridger GP (2001). Regulation of prostate branching morphogenesis by activin A and follistatin. Dev Biol 237, 145-158.
67. Mellor SL, Richards MG, Pedersen JS, Robertson DM, and Risbridger GP (1998). Loss of the expression and localization ofinhibin alpha-subunit in high grade prostate cancer. /Clin Endocrinol Metab 83, 969-975. (Pubitemid 28496478)
68. Ying C, Zhang Z, and Ying SY (1995). Expression and localization of activin beta A-subunit and activin receptors in TM3, a mouse Leydig cell line. Endocr Res 21, 815-824.
69. Gray PC, Greenwald J, Blount AL, Kunitake KS, Donaldson CJ, Choe S, and Vale W (2000). Identification of a binding site on the type II activin receptor for activin and inhibin, J. Biol Chem 275, 3206-3212. (Pubitemid 30083020)
70. Xu J, McKeehan K, Matsuzaki K, and McKeehan WL (1995). Inhibin antago- nizes inhibition of liver cell growth by activin by a dominant-negative mecha- nism. J. Biol Chem 270, 6308-6313.
71. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, and Bradley A (1992). alpha- Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360, 313-319. (Pubitemid 23000668)
72. Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K, and Gerber B (2005). Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially ex- pressed in human, breast cancer and their metastasis. Oncol Rep 13, 81-88.
73. Wang M, Liu A, Garcia FU, Rhim JS, and Steams ME (1999). Growth of HPV-18 immortalized human prostatic intraepithelial neoplasia cell lines. Influ- ence ofIL-10, follistatin, activin-A, and DHT. IntJOncolU, 1185-1195.
74. McPherson SJ, Thomas TZ, Wang H, Gurusinghe CJ, and. Risbridger GP (1997). Growth inhibitory response to activin A and B by human prostate tu- mour cell lines, LNCaP and DU145. J. Endocrinol 154, 535-545. (Pubitemid 27375049)
75. Zhang Z, Zhao Y, Batres Y, Lin MF, and Ying SY (1997). Regulation of growth and prostatic marker expression, by activin A in an androgen-sensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun 234, 362-365. (Pubitemid 27243908)
76. Schally AV (2005). [The discovery of hypothalamic hormones and the develop- ment of antitumor analogs]. Ann Urol (Paris) 39 (Suppl 3), S46-S50.
77. Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, and Candas B (2005). Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26, 361-379. (Pubitemid 40686649)
78. Wild! S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, and Korc M (2001). Overexpression of activin A in stage IV colorectal, cancer. Gut 49, 409-417.
79. Yoshinaga K, Mimori K, Yamashita K, Utsunomiya T, Inoue H, and. Mori M (2003). Clinical significance of the expression of activin A in esophageal carci- noma. IntJ Oncol 22, 75-80.
80. Lambert-Messerlian GM, DePasquale SE, Maybruck WM, Steinhoff MM, and Gajewski WH (1999). Secretion of activin A in recurrent epithelial ovarian car- cinoma. Gynecol Oncol 74, 93-97. (Pubitemid 29331173)
81. Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Vigano P, Di Blasio AM, Genazzani AR, and Vale W (1998). Expression and secretion, of inhibin and ac- tivin in normal, and neoplastic uterine tissues. High levels of serum, activin A in women with endometrial and cervical carcinoma. J. Clin Endocrinol Metab 83, 1.1.94-1200. (Pubitemid 28496392)
82. Mori H, Maki M, Oishi K, Jaye M, Igarashi K, Yoshida O, and Hatanaka M (1990). Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate 16, 71-80. (Pubitemid 20127960)
83. Cohen RJ, Glezerson G, and Haffejee Z (1991). Neuro-endocrine cells-a new prognostic parameter in prostate cancer. Br J Urol 66, 258-262.
84. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, and Rubin JS (1992). Human prostate cancer model: roles of growth factors and extracellular matrices. J. Cell Biochem Suppl 16H, 99-105. (Pubitemid 23047980)
85. Comoglio PM and Trusolino L (2002). Invasive growth: from development to metastasis. J. Clin Invest 109, 857-862. (Pubitemid 34275105)
86. Cunha GR, Hayward SW, and Wang YZ (2002). Role of stroma in carcinogene- sis of the prostate. Differentiation 70, 473-485. (Pubitemid 36194313)
87. Sung SY and Chung LW (2002). Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 70, 506-521. (Pubitemid 36194316)
88. Story MT (1995). Regulation of prostate growth by fibroblast growth factors. World J Urol 13, 297-305.
89. Story MT, Livingston B, Baeten L, Swartz SJ, Jacobs SC, Begun FP, and Lawson RK (1989). Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 15, 355-365. (Pubitemid 20084722)
90. Sherwood ER, Fong CJ, Lee C, and Kozlowski JM (1992). Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Endocrinology 130, 2955-2963.
91. Alarid ET, Rubin JS, Young P, Chedid M, Ron D, Aaronson SA, and Cunha GR (1994). Keratinocyte growth factor functions in epithelial induction during seminal veside development. Proc Natl Acad Sei USA 91, 1074-1078. (Pubitemid 24048511)
92. Cohen P, Peehl DM, Lamson G, and Rosenfeld RG (1991). Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin Endocrinol Metab 73, 401-407. (Pubitemid 21921888)
93. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, and Cordon-Cardo C (1994). Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. /Urol 152, 2120-2124. (Pubitemid 24354757)
94. Freeman MR, Paul. S, Kaefèr M, Ishikawa M, Adam RM, Renshaw AA, Elenius K, and Klagsbrun M (1998). Heparin-binding EGF-like growth, factor in the hu- man prostate: synthesis predominantly by interstitial and vascular smooth musde cells and action as a carcinoma cell mitogen. J. Cell Biochem 68, 328-338. (Pubitemid 28080125)
95. Sciavoli.no PJ and Abate-Shen C (1998). Molecular biology of prostate develop- ment and prostate cancer. Ann Med 30, 357-368.
96. Giri D, Ropiquet F, and Ittmann M (1999). FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J. Cell Physiol 180, 53-60. (Pubitemid 29249712)
97. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Onega S, Basilico C, and Ittmann M (2003). Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 63, 5754-5760. (Pubitemid 37187471)
98. Najy AJ, Day KC, and Day ML (2008). ADAM 15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res 68, 1092-1099.
99. Perttu MC, Martikainen PM, Huhtala HS, Blauer M, Tammela TL, Tuohimaa PJ, and Syvala H (2006). Altered levels of Smad2 and Smad4 are associated with human prostate carcinogenesis. Prostate Cancer Prostatic Dis 9, 185-189. (Pubitemid 43970969)
100. Vadakkadath Meethal S and Atwood CS (2005). The role of hypothalamic- pituitary-gonadal hormones in the normal structure and functioning of the brain, Cell MoI Life Set 62, 257-270. (Pubitemid 40379241)